| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Marco Zucconi, Luigi Ferini-Stramb. Epidemiology and clinical findings of restless legs syndrome. Sleep medicine. vol 5. issue 3. 2004-09-28. PMID:15165538. |
response to dopaminergic drugs indicates that dopamine receptors are implicated, and although much progress has been made in diagnosis and treatment in the last decade, more is needed for complete elucidation of the etiology and pathophysiology of rls. |
2004-09-28 |
2023-08-12 |
Not clear |
| Manuela Contin, Paolo Martinelli, Mirella Mochi, Fiorenzo Albani, Roberto Riva, Cesa Scaglione, Maurizio Dondi, Stefano Fanti, Cinzia Pettinato, Agostino Baruzz. Dopamine transporter gene polymorphism, spect imaging, and levodopa response in patients with Parkinson disease. Clinical neuropharmacology. vol 27. issue 3. 2004-09-27. PMID:15190232. |
to assess the potential association between dopamine transporter (dat) genotype, single photon emission ct (spect) measures using [123i]-n-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl)nortropane ([123i]-fp-cit) of striatal dopaminergic function, and oral levodopa response pattern in a cohort of patients with parkinson disease. |
2004-09-27 |
2023-08-12 |
Not clear |
| M Pohanka, P Kanovský, M Bares, J Pulkrábek, I Rekto. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. European journal of neurology. vol 11. issue 7. 2004-09-24. PMID:15257688. |
the effect of dopamine replacement or dopaminergic stimulation on sexual dysfunction has been recently examined and described in patients treated by l-dopa or apomorphine. |
2004-09-24 |
2023-08-12 |
Not clear |
| M Pohanka, P Kanovský, M Bares, J Pulkrábek, I Rekto. Pergolide mesylate can improve sexual dysfunction in patients with Parkinson's disease: the results of an open, prospective, 6-month follow-up. European journal of neurology. vol 11. issue 7. 2004-09-24. PMID:15257688. |
pergolide mesylate is another dopamine agonist with a known high affinity to hd(2s) subtype and a lower affinity to hd(2l) subtype of d2 dopaminergic receptors. |
2004-09-24 |
2023-08-12 |
Not clear |
| Patricia Robledo, Victoria Mendizabal, Jordi Ortuño, Rafael de la Torre, Brigitte L Kieffer, Rafael Maldonad. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. The European journal of neuroscience. vol 20. issue 3. 2004-09-21. PMID:15255997. |
these differences could be due to distinct mechanisms controlling dopamine release in the nucleus accumbens and suggest that the effects of mdma on dopaminergic neurons are independent of micro -opioid receptors. |
2004-09-21 |
2023-08-12 |
mouse |
| S Asai, R Ohta, M Shirota, A Tohei, G Watanabe, K Tay. Endocrinological responses during suckling in Hatano high- and low-avoidance rats. The Journal of endocrinology. vol 182. issue 2. 2004-09-20. PMID:15283687. |
since dopamine from the median eminence inhibits prolactin secretion from the lactotrophs of the anterior pituitary, and tuberoinfundibular dopaminergic neurones are partially regulated by the level of circulating prolactin, we evaluated the activity of tyrosine hydroxylase (th), the rate-limiting enzyme in dopamine biosynthesis. |
2004-09-20 |
2023-08-12 |
rat |
| Mirthe M Ponsen, Diederick Stoffers, Jan Booij, Berthe L F van Eck-Smit, Erik Ch Wolters, Henk W Berends. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Annals of neurology. vol 56. issue 2. 2004-09-20. PMID:15293269. |
a combination of olfactory detection, identification, and discrimination tasks was used to select groups of hyposmic (n = 40) and normosmic (n = 38) individuals for a 2-year clinical follow-up evaluation and sequential single-photon emission computed tomography (spect), using [123i]beta-cit as a dopamine transporter ligand, to assess nigrostriatal dopaminergic function at baseline and 2 years from baseline. |
2004-09-20 |
2023-08-12 |
Not clear |
| Tatiana M Korotkova, Alexei A Ponomarenko, Ritchie E Brown, Helmut L Haa. Functional diversity of ventral midbrain dopamine and GABAergic neurons. Molecular neurobiology. vol 29. issue 3. 2004-09-16. PMID:15181237. |
the electrophysiological properties of subgroups of gabaergic midbrain neurons, patterns of expression of protein markers and receptors, possible involvement of gabaergic neurons in a number of processes that are usually attributed exclusively to dopaminergic neurons, and the characteristics of a subgroup of neurons that contains both dopamine and gaba are also discussed. |
2004-09-16 |
2023-08-12 |
Not clear |
| Jing Zhang, David R Goodlet. Proteomic approach to studying Parkinson's disease. Molecular neurobiology. vol 29. issue 3. 2004-09-16. PMID:15181239. |
parkinson's disease is a common age-related neurodegenerative disease characterized pathologically by a loss of dopaminergic neurons in the substantia nigra with resultant depletion of striatal dopamine and presence of lewy bodies in the remaining neurons. |
2004-09-16 |
2023-08-12 |
human |
| M Orth, S J Tabrizi, C Tomlinson, K Messmer, L V P Korlipara, A H V Schapira, J M Coope. G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochemistry international. vol 45. issue 5. 2004-09-16. PMID:15234109. |
this may result in increased dopamine metabolism and cause selective oxidative damage to dopaminergic cells. |
2004-09-16 |
2023-08-12 |
Not clear |
| Günter U Höglinger, Pamela Rizk, Marie P Muriel, Charles Duyckaerts, Wolfgang H Oertel, Isabelle Caille, Etienne C Hirsc. Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nature neuroscience. vol 7. issue 7. 2004-09-14. PMID:15195095. |
here we provide ultrastructural evidence showing that highly proliferative precursors in the adult subependymal zone express dopamine receptors and receive dopaminergic afferents. |
2004-09-14 |
2023-08-12 |
Not clear |
| Thomas N Chas. Striatal plasticity and extrapyramidal motor dysfunction. Parkinsonism & related disorders. vol 10. issue 5. 2004-09-14. PMID:15196510. |
studies in animal models as well as in patients afflicted by this disorder suggest that the nonphysiologic stimulation of striatal dopamine receptors, first as a result of dopaminergic denervation and later as a consequence of the intermittent high-intensity stimulation produced by standard therapeutic regimens, leads to plastic changes in striatal medium spiny neurons. |
2004-09-14 |
2023-08-12 |
Not clear |
| Chuantao Jiang, Xinhua Wan, Joseph Jankovic, Samuel T Christian, Zdenek B Pristupa, Hyman B Niznik, John S Sundsmo, Weidong L. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clinical neuropharmacology. vol 27. issue 2. 2004-09-09. PMID:15252266. |
with a view toward improving the neural bioavailability of administered dopaminergic compounds, including dopamine, synthetic efforts have been directed toward enhancing the brain bioavailability of these compounds by accessing cellular sugar transport systems with stereoselective dopaminergic drugs. |
2004-09-09 |
2023-08-12 |
mouse |
| Chuantao Jiang, Xinhua Wan, Joseph Jankovic, Samuel T Christian, Zdenek B Pristupa, Hyman B Niznik, John S Sundsmo, Weidong L. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clinical neuropharmacology. vol 27. issue 2. 2004-09-09. PMID:15252266. |
one member of this new class, ipx-750, is a pro-drug dopamine-gluconamine designed to retain stereospecificity of binding at: glucose transporters (glut 1/glut 3 and intestinal na/glucose co-transporters sglt1), dopamine transporter (dat); and, dopaminergic receptors of the d1/d2 families. |
2004-09-09 |
2023-08-12 |
mouse |
| Chuantao Jiang, Xinhua Wan, Joseph Jankovic, Samuel T Christian, Zdenek B Pristupa, Hyman B Niznik, John S Sundsmo, Weidong L. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clinical neuropharmacology. vol 27. issue 2. 2004-09-09. PMID:15252266. |
these combined results suggest (i) that stereo-specific glycoconjugation may be an effective method to improve penetrability of drugs through the blood brain barrier; (ii) treatment with bioavailable ipx-750 in vitro did not show evidence for neurotoxicity; and, (iii) ipx-750 possesses dopaminergic properties and exerts anti-parkinsonian effects in three different pd rodent models, suggesting therapeutic potential for this new class of drugs in treating dopamine deficiency diseases. |
2004-09-09 |
2023-08-12 |
mouse |
| Shaun Jordan, Vuk Koprivica, Robert Dunn, Katsura Tottori, Tetsuro Kikuchi, C Anthony Alta. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. European journal of pharmacology. vol 483. issue 1. 2004-09-07. PMID:14709325. |
together, these data provide in vivo evidence of aripiprazole-induced changes in forebrain dopaminergic and serotonergic function that may reflect its partial agonist activity at presynaptic dopamine d(2) and 5-ht(1a) receptors and antagonist activity at 5-ht(2a) receptors. |
2004-09-07 |
2023-08-12 |
rat |
| Anthony DeLeon, Nick C Patel, M Lynn Crismo. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical therapeutics. vol 26. issue 5. 2004-09-03. PMID:15220010. |
aripiprazole is considered a partial dopaminergic agonist, acting on both postsynaptic dopamine(2) receptors and presynaptic autoreceptors, in addition to displaying partial agonism at serotonin(1a) receptors and antagonism at serotonin(2a) receptors. |
2004-09-03 |
2023-08-12 |
Not clear |
| Jean-Christophe Rochet, Tiago Fleming Outeiro, Kelly A Conway, Tomas T Ding, Michael J Volles, Hilal A Lashuel, Robert M Bieganski, Susan L Lindquist, Peter T Lansbur. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. Journal of molecular neuroscience : MN. vol 23. issue 1-2. 2004-09-01. PMID:15126689. |
this finding suggests that cytosolic dopamine in dopaminergic neurons promotes the accumulation of toxic alpha-synuclein protofibrils, which might explain why these neurons are most vulnerable to degeneration in pd. |
2004-09-01 |
2023-08-12 |
Not clear |
| Kevin St P McNaught, Daniel P Perl, Anna-Liisa Brownell, C Warren Olano. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Annals of neurology. vol 56. issue 1. 2004-08-31. PMID:15236415. |
postmortem analyses showed striatal dopamine depletion and dopaminergic cell death with apoptosis and inflammation in the substantia nigra pars compacta. |
2004-08-31 |
2023-08-12 |
rat |
| Giorgio Racagni, Pier Luigi Canonico, Luigi Ravizza, Luca Pani, Mario Amor. Consensus on the use of substituted benzamides in psychiatric patients. Neuropsychobiology. vol 50. issue 2. 2004-08-31. PMID:15292667. |
at low doses (50 mg), amisulpride preferentially blocks presynaptic autoreceptors, producing an increase in dopamine release, and therefore acting as a dopaminergic compound able to resolve the dopaminergic hypoactivity that characterizes depression. |
2004-08-31 |
2023-08-12 |
Not clear |